Astrazeneca, Daiichi Sankyo Begin Phase 3 Trial of Enhertu Combination in Ovarian Cancer

MT Newswires Live12-09

Astrazeneca (AZN) and Daiichi Sankyo said Tuesday that the first patient has been dosed in a phase 3 trial evaluating Enhertu in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy for a type of ovarian cancer.

The companies said the study is being carried out in collabaration with the European Network of Gynecological Oncological Trial Groups, with the Spanish group GEICO serving as the lead ENGOT group, along with The GOG Foundation and the Asia-Pacific Gynecologic Oncology Trials Group.

The trial's primary endpoint is progression-free survival assessed by blinded independent central review, with overall survival as the key secondary endpoint, the companies said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590341498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590341498","market":"fut","top_or_hot":-1,"title":"Astrazeneca, Daiichi Sankyo Begin Phase 3 Trial of Enhertu Combination in Ovarian Cancer","media":"MT Newswires Live","content":"<html><body><p> Astrazeneca (AZN) and <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> said Tuesday that the first patient has been dosed in a phase 3 trial evaluating Enhertu in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy for a type of ovarian cancer.</p><p>The companies said the study is being carried out in collabaration with the European Network of Gynecological Oncological Trial Groups, with the Spanish group GEICO serving as the lead ENGOT group, along with The GOG Foundation and the Asia-Pacific Gynecologic Oncology Trials Group.</p><p>The trial's primary endpoint is progression-free survival assessed by blinded independent central review, with overall survival as the key secondary endpoint, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca, Daiichi Sankyo Begin Phase 3 Trial of Enhertu Combination in Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca, Daiichi Sankyo Begin Phase 3 Trial of Enhertu Combination in Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Astrazeneca (AZN) and <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> said Tuesday that the first patient has been dosed in a phase 3 trial evaluating Enhertu in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy for a type of ovarian cancer.</p><p>The companies said the study is being carried out in collabaration with the European Network of Gynecological Oncological Trial Groups, with the Spanish group GEICO serving as the lead ENGOT group, along with The GOG Foundation and the Asia-Pacific Gynecologic Oncology Trials Group.</p><p>The trial's primary endpoint is progression-free survival assessed by blinded independent central review, with overall survival as the key secondary endpoint, the companies said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590341498","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590341498","pubTimestamp":1765288057,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Astrazeneca  and Daiichi Sankyo said Tuesday that the first patient has been dosed in a phase 3 trial evaluating Enhertu in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy for a type of ovarian cancer.The companies said the study is being carried out in collabaration with the European Network of Gynecological Oncological Trial Groups, with the Spanish group GEICO serving as the lead ENGOT group, along with The GOG Foundation and the Asia-Pacific Gynecologic Oncology Trials Group.The trial's primary endpoint is progression-free survival assessed by blinded independent central review, with overall survival as the key secondary endpoint, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4568":"美国抗疫概念","BK4588":"碎股","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"阿斯利康、第一三共开始Enhertu组合治疗卵巢癌的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"Astrazeneca (AZN) and Daiichi Sankyo said Tuesday that the first patient has been dosed in a phase 3 trial evaluating Enhertu in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy for a type of ovarian cancer.The companies said the study is being carried out in collabaration with the European Network of Gynecological Oncological Trial Groups, with the Spanish group GEICO serving as the lead ENGOT group, along with The GOG Foundation and the Asia-Pacific Gynecologic Oncology Trials Group.The trial's primary endpoint is progression-free survival assessed by blinded independent central review, with overall survival as the key secondary endpoint, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590341498","isCrawlerRequest":true}